GSK starts work on new £100 million India facility

10 September 2015

UK pharma major GlaxoSmithKline (LSE: GSK) said it has started work on its new manufacturing facility in the South-Indian state of Karnataka.

The company is investing £100 million ($153.7 million) in the factory to produce 8 billion tablets and 1 billion capsules for the Indian market. The new factory will be built on a 50-acre site and employ about 300 people once it becomes operational. GSK said the facility will be fully operational in 2017.

Annaswamy Vaidheesh, managing director of GlaxoSmithKline Pharmaceuticals India, said: “We fully support the government in their efforts to increase access to affordable medicines to improve healthcare and we are very excited to begin work on what will become our largest manufacturing facility in India. With this new facility, we aim to further strengthen our commitment to helping the patients in India to improve their health and wellbeing.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK